drugset / Trial / NCT01718145
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subject. The purpose of this study is to compare the anti-viral activity of the co-administration of Asunaprevir (ASV) and Daclatasvir (DCV) to Telaprevir (TVR) included therapy in Japanese Hepatitis C virus (HCV) subjects
Timeline
- Start
- 2012-11
- Primary completion
- 2013-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asunaprevir | Small molecule | 200 mg | Oral |
| Subject | Daclatasvir | Small molecule | 60 mg | Oral |
| Comparator | Telaprevir | Small molecule | 750 mg | Oral |
| Comparator | Peginterferon alfa-2b | Protein / enzyme biologic | 1.5 ug/kg | Subcutaneous |
| Comparator | Ribavirin | Small molecule | 600 mg | Oral |
| Comparator | Ribavirin | Small molecule | 1000 mg | Oral |